Neostigmin Unimedic Pharma Ab (Neostigmine Methylsulfate)

Neostigmine methylsulfate, the active ingredient in Neostigmin Unimedic Pharma Ab, is a cholinesterase inhibitor presented as a sterile solution for intravenous and subcutaneous use. It is employed to improve neuromuscular transmission in myasthenia gravis, to reverse non‑depolarizing neuromuscular blockade after surgery, and to stimulate bowel motility in postoperative ileus.

GNH USA supplies Neostigmin Unimedic Pharma Ab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neostigmine methylsulfate acts on the cholinergic neuromuscular system and is indicated for several clinical conditions: - Myasthenia gravis: enhances muscle strength by increasing acetylcholine at the neuromuscular junction. - Reversal of non‑depolarizing neuromuscular blockade: restores spontaneous breathing after anesthesia. - Post‑operative ileus: stimulates intestinal motility to reduce postoperative bowel paralysis.

Neostigmine methylsulfate may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Abdominal cramps: mild to moderate discomfort in the abdomen. - Diarrhea: increased frequency of loose stools. - Nausea: sensation of unease and urge to vomit. - Increased salivation: excess oral secretions. - Sweating: generalized hyperhidrosis. - Muscle fasciculations: brief, involuntary muscle twitches.

Serious or Rare Side Effects: - Bradycardia: significant slowing of heart rate requiring monitoring. - Bronchospasm: constriction of airway muscles leading to breathing difficulty. - Seizures: rare central nervous system excitation. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, urticaria, or anaphylaxis. - Persistent muscle weakness: may indicate over‑dosage or cholinergic crisis.

Neostigmine methylsulfate should be used with careful clinical assessment and monitoring. - Cardiac monitoring: observe heart rate and rhythm, especially in patients with pre‑existing cardiac disease. - Respiratory assessment: ensure adequate ventilation, particularly after reversal of neuromuscular blockade. - Renal impairment: adjust dosing or monitor closely in patients with reduced kidney function. - Concomitant anticholinergic drugs: avoid or stagger administration to prevent antagonistic effects. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store below 25°C: keep in the original container, protect from light and moisture.

Neostigmine methylsulfate can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may exacerbate bradycardia. - Calcium channel blockers: increase risk of severe hypotension. - Other cholinesterase inhibitors: additive cholinergic effects can precipitate crisis.

Moderate Interactions (Monitor Closely): - Anticholinergic agents (e.g., atropine, scopolamine): may reduce therapeutic effect. - Aminoglycoside antibiotics: potentiate neuromuscular blockade. - Diuretics: may affect electrolyte balance, influencing neuromuscular transmission.